Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals - Whitman-Walker

Masking Status:

Recommended

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

You might also be interested in

Front Page News, News, Press & Media

November 7, 2024

Whitman-Walker Health System announces the appointment of Ted Miller as Interim Executive Director of the Whitman-Walker Foundation

News, Press & Media

November 1, 2024

Whitman-Walker Health CEO named to Washington Business Journal’s 2024 List of Women Who Mean Business

Institute, News, Policy, Press & Media

September 19, 2024

Serious Inquiries Only Podcast: Actual Experts Debunk the Cass Review